Table 1 Adjustment for traditional risk factors in studies of C-reactive protein and cardiovascular risk

Modifiable risk factors adjusted for in published analysis
Study / Year / Patients / LDL / Triglycerides / HDL / WC/BMI / Glucose / BP
MRFIT1 / 1996 / High Framingham-risk men / Yes / Yes / Yes / No / Yes / Yes
Physician’s Health Study2 / 1998 / Apparently healthy men / No / No / No / Yes / Yes / Yes
MONICA3 / 1999 / Healthy middle-aged men / No / No / Yes / Yes / Yes / Yes
Hoorn Study4 / 1999 / Middle-aged men and women / No / Yes / Yes / Yes / Yes / Yes
Caerphilly Study5 / 2000 / Middle-aged men with ischemic heart disease / No / No / Yes / Yes / No / Yes
AFCAPS/TEXCAPS6 / 2001 / Middle-aged men and postmenopausal women with average levels of total and LDL cholesterol and below-average levels of HDL cholesterol / Yes / No / Yes / No / No / Yes
WOSCOPS7 / 2003 / Metabolic Syndrome / Yes / Yes / Yes / No / No / No
Women’s Health Study8 / 2003 / Postmenopausal women / No / No / No / Yes / Yes / Yes
Rotterdam Study9 / 2003 / Men and women aged over 55 years / No / No / Yes / Yes / Yes / Yes
ARIC10 / 2004 / Middle-aged men and women / No / No / Yes / No / Yes / Yes
Reykjavik Study11 / 2004 / Middle-aged men and women without history of MI / No / No / No / Yes / Yes / Yes
Framingham Offspring Study12 / 2004 / Metabolic syndrome / No / No / No / Yes / Yes / Yes
PROVE-IT13 / 2005 / Acute coronary syndrome / Yes / No / No / Yes / Yes / Yes
NHANES14 / 2005 / Adults 18 years or older / No / Yes / Yes / Yes / Yes / Yes
JUPITER15 / - / hs-CRP levels 2 mg/l or higher ;LDL- cholesterol levels lower than 130 mg/dl (3.36 mmol/l) / Yes / No / No / Yes / Yes / Yes

Abbreviations: AFCAPS/TEXCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; Hs-CRP, high-sensitivity C-reactive protein; JUPITER, Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL, low-density lipoprotein; MI, myocardial infarction; MONICA, Monitoring Trends and Determinants in Cardiovascular Disease; MRFIT, Multiple Risk Factor Intervention Trial; NHANES, National Health and Nutrition Examination Survey; PROVE-IT, Pravastatin or Atorvastatin Evaluation and Infection Therapy; WC, waist circumference; WOSCOPS, West of Scotland Coronary Prevention Study.

References

1 Kuller LH et al. (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case–control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144: 537–547

2 Ridker PM et al. (1998) C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97: 2007–2011

3 Koenig W et al. (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237–242

4 Jager A et al. (1999) von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19: 3071–3078

5 Mendall MA et al. (2000) C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 21: 1584–1590

6 Ridker PM et al. for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959–1965

7 Sattar N et al. (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108: 414–419

8 Ridker PM et al. (2003) C-Reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107: 391–397

9 Van der Meer IM et al. (2003) The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 163: 1323–1328

10 Ballantyne CM et al. (2004) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109: 837–842

11 Danesh J et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387–1397

12 Rutter MK et al. (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110: 380–385

13 Ridker PM et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) Investigators (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28

14 Miller M et al. (2005) High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 165: 2063–2068

15 Ridker PM for the JUPITER Study Group (2003) Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108: 2292–2297